Vanguard Capital Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
Vanguard Capital Management's VRDN Position: Q3 2026 in Review
Vanguard Capital Management increased its Viridian Therapeutics (VRDN) stake by 3.9% in Q3 2026, buying an estimated $3.79M and bringing the position to 4,754,495 shares worth $97.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1539.
Vanguard Capital Management first reported a position in VRDN in Q1 2026 and has held it in 3 quarters since. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Vanguard Capital Management held 4,754,495 shares of Viridian Therapeutics worth $97.9M as of Q3 2026.
- Vanguard Capital Management bought 177,635 Viridian Therapeutics shares in Q3 2026, an estimated $3.79M.
- Viridian Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1539 holding.
- Vanguard Capital Management first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.